Komori
Earnings4892Cyfuse Biomedical K.K.Pharmaceuticals

Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 (Japanese GAAP, Non-consolidated)

Interim-period net sales increased 254.6% year on year to ¥104 million, while the operating loss narrowed to ¥417 million. However, ordinary loss and interim net loss widened due to a decrease in non-operating income and an increase in non-operating expenses. The full-year earnings forecast remains unchanged.

Worth reading
40Recurring
Scored from 5 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
254.6
%
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 January 2026–30 June 2026Non-consolidated (standalone)Japanese GAAP
Net Sales104¥ millionYear on year +254.6%Progress 37.4%
Operating profit-417¥ million
Ordinary income-433¥ million
Net income attributable to owners of the parent-434¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share−¥43.46
Financial position at period-end
Total assets3,925¥ million
of which net assets 2,622 ¥ millionEquity ratio 63.6%vs. prior year-end +1.3pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-443,071
Investment-200,626
Financials+108,689
Net change-535,008

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥1,841,527 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥278 million (YoY +20.4%)
Operating profit¥-1,081 million
Ordinary income¥-1,056 million
Net income¥-1,059 million
Annual Dividend Forecast¥0.00 → ¥0.00(0%)
Factors Behind Changes in Business Performance

Net sales increased due to various contract services related to 3D cell products and sales of related consumables. The operating loss narrowed due to a decrease in selling, general and administrative expenses, while ordinary loss and interim net loss widened due to a decrease in non-operating income and an increase in non-operating expenses.

Disclosure regarding the going concern assumption

No applicable matters. The notes on the going concern assumption state that there are no applicable matters.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsNot applicable.
Depreciation and amortization¥12,302 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End10,092,100 shares
Treasury Shares at Period-End— shares
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 January 2026–30 June 2026
Net Sales¥104 million (YoY +254.6%)
Operating profit¥-417 million
Ordinary income¥-433 million
Profit attributable to owners of the parent¥-434 million
Net income per share−¥43.46
Equity ratioEnd of the current fiscal period 63.6% / End of previous period 62.3%
Total assets¥3,925 million
Net assets¥2,622 million
Cash flows from operating activities¥-443,071 thousand
Cash flows from investing activities¥-200,626 thousand
Cash flows from financing activities¥108,689 thousand
Cash and cash equivalents at end of period¥1,841,527 thousand
Full-year earnings forecastNet Sales ¥278 million (YoY +20.4%) / Operating profit ¥-1,081 million / Ordinary income ¥-1,056 million / Net income ¥-1,059 million
Annual Dividend Forecast¥0.00 → ¥0.00(0%)
Depreciation and amortization¥12,302 thousand
Disclosure regarding the going concern assumptionNo applicable matters. The notes on the going concern assumption state that there are no applicable matters.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Material subsequent eventsNot applicable.
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End10,092,100 shares
Treasury Shares at Period-End— shares
Factors Behind Changes in Business PerformanceNet sales increased due to various contract services related to 3D cell products and sales of related consumables. The operating loss narrowed due to a decrease in selling, general and administrative expenses, while ordinary loss and interim net loss widened due to a decrease in non-operating income and an increase in non-operating expenses.
Items this document does not state (11)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidation

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Net sales increased due to various contract services related to 3D cell products and sales of related consumables. The operating loss narrowed as selling, general and administrative expenses decreased 0.7% year on year. However, ordinary loss and interim net loss widened because non-operating income decreased 86.3% and non-operating expenses increased 94.3%.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 (Japanese GAAP, Non-consolidated) | Cyfuse Biomedical K.K. (4892) timely disclosure | Komori